Opendata, web and dolomites

EURE-CART SIGNED

EURopean Endeavour for Chimeric Antigen Receptor Therapies

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 EURE-CART project word cloud

Explore the words cloud of the EURE-CART project. It provides you a very rough idea of what is the project "EURE-CART" about.

chimeric    causes    causing    demonstrated    academic    stage    create    cells    personalised    tumour    respective    eure    expensive    regulatory    diseases    countries    gene    constrains    academia    cell    applicability    man    trial    reactive    anti    jobs    molmed    representing    involvement    pioneers    unparalleled    extend    enterprise    centres    excellences    bodies    centralisation    defeating    car    though    adoptive    frequent    oncology    unprecedented    therapies    approval    industry    accelerating    leaders    therapeutic    alliance    cart    secure    never    ultimate    enormously    national    record    endowed    conducting    establishment    antigen    smes    secondary    experts    tumours    genetically    billions    innovative    cancer    successful    clinical    death    tackled    chronic    eradicate    spa    receptor    eur    first    therapy    meet    immunotherapy    proposes    instalment    forefront    incurable    uniquely    struggles    modified    track   

Project "EURE-CART" data sheet

The following table provides information about the project.

Coordinator
MOLECULAR MEDICINE SPA 

Organization address
address: VIA OLGETTINA 58
city: MILANO
postcode: 20132
website: www.molmed.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website https://www.eure-cart.eu/
 Total cost 5˙903˙146 €
 EC max contribution 5˙903˙146 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2016-RTD
 Funding Scheme RIA
 Starting year 2017
 Duration (year-month-day) from 2017-01-01   to  2020-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MOLECULAR MEDICINE SPA IT (MILANO) coordinator 1˙994˙575.00
2    OSPEDALE SAN RAFFAELE SRL IT (MILANO) participant 1˙112˙500.00
3    UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT DE (WURZBURG) participant 856˙076.00
4    OSPEDALE PEDIATRICO BAMBINO GESU IT (ROMA) participant 492˙431.00
5    ACROMION GMBH DE (FRECHEN) participant 398˙000.00
6    ARTTIC FR (PARIS) participant 375˙000.00
7    FUNDACIO PRIVADA INSTITUT DE RECERCA DE L'HOSPITAL DE LA SANTA CREU I SANT PAU ES (BARCELONA) participant 225˙011.00
8    ISTITUTO SUPERIORE DI SANITA IT (ROMA) participant 225˙000.00
9    FAKULTNI NEMOCNICE OSTRAVA CZ (OSTRAVA PORUBA) participant 224˙552.00

Map

 Project objective

Cancer is rapidly becoming the most frequent cause of death in EU. Though enormously expensive (several billions EUR/year), currently available anti-cancer therapies are major causes of chronic diseases. Adoptive immunotherapy with T cells genetically modified with a tumour-reactive chimeric antigen receptor (CAR) is an innovative therapeutic concept, promising to eradicate cancer without causing secondary chronic diseases. This approach is already at an advanced stage of development in the US, but struggles in the EU, due to a number of constrains that will be specifically tackled by this Project. The ultimate goal of EURE-CART is to bring EU at the forefront CAR T-cell immunotherapy. In this Project, we will extend the applicability of CAR T-cell immunotherapy to incurable tumours that have never been tackled with this approach. The EURE-CART Consortium is composed of 6 academic centres, 2 SMEs and 1 large enterprise from 6 EU countries, clearly representing excellences in their respective fields. EURE-CART will bring together clinical experts in oncology, and pioneers and leaders in the field of cell and gene therapy for conducting a first-in-man Phase I/II clinical trial. To be successful, EURE-CART proposes the early involvement of National regulatory authorities for accelerating the approval of CAR T-cell immunotherapy, as well as the centralisation of its production by the Molmed Spa. Molmed Spa is uniquely endowed in the EU with the know-how and experience necessary to meet this ambitious objective, as demonstrated by its unparalleled track record. The main expected impact of EURE-CART is the establishment of CAR T-cell therapy as the ultimate personalised therapy, capable of defeating chronic diseases, and to create secure new jobs in the EU through the instalment of an unprecedented alliance between academia, industry and regulatory bodies.

 Deliverables

List of deliverables.
Preparation of a project logo and flyer Websites, patent fillings, videos etc. 2019-05-31 16:44:17
Individualised press releases Websites, patent fillings, videos etc. 2019-05-31 17:41:12
Signing-up of dedicated Twitter and LinkedIn accounts Websites, patent fillings, videos etc. 2019-05-31 17:41:08
Launch of dedicated website Websites, patent fillings, videos etc. 2019-05-31 16:44:21

Take a look to the deliverables list in detail:  detailed list of EURE-CART deliverables.

 Publications

year authors and title journal last update
List of publications.
2018 \"\"\"F. Moretti, F. Capone, C. Traversari, M.C. Galli\"
Il Progetto europeo EURE-CART: l\'ISS tra i partner del nuovo approccio terapeutico e personalizzato per sconfiggere le malattie neoplastiche
published pages: 3-5, ISSN: 1827-6296, DOI:
Notiziario Istituto Superiore Sanità 31(11) 2020-03-05
2018 Franco Locatelli, Concetta Quintarelli
The EURE-CART project as a prototype model for CAR T-cell immunotherapy in Europe
published pages: 216-219, ISSN: 0014-2980, DOI: 10.1002/eji.201870029
European Journal of Immunology 48/2 2019-06-11

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EURE-CART" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EURE-CART" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

INTE-AFRICA (2019)

Integrating and decentralising diabetes and hypertension services in Africa

Read More  

FAIR (2020)

FLAGELLIN AEROSOL THERAPY AS AN IMMUNOMODULATORY ADJUNCT TO THE ANTIBIOTIC TREATMENT OF DRUG-RESISTANT BACTERIAL PNEUMONIA

Read More